One main problem in any surgery is access to the operative site: This means cutting through and bleeding from healthy tissue with infections, scars, pain, prolonged hospital stays and costs. Focal therapy with HIFU takes this burden out of the equation, which has been any surgeon's dream for centuries.Read more
EDAP TMS’s Focal One system could see faster uptake as more doctors use it for less invasive treatment in prostate care and potentially endometriosis, helped by new features and growing awareness among patients. But the story hinges on one core technology and on hospitals and insurers staying supportive, with regulatory delays and rising costs as key obstacles.Read more
Key Takeaways Rapid adoption of minimally invasive HIFU technology and improved reimbursement is driving market expansion, higher procedure revenue, and deeper hospital network penetration. New therapeutic indications, growing recurring revenue, and strengthened global operations position EDAP for sustained multi-year growth and greater earnings visibility.Read more
Key Takeaways Over-reliance on HIFU technology and delayed reimbursement approvals could limit revenue growth and make the company vulnerable to shifts in clinical practice. Global cost pressures, geopolitical risks, and ongoing operating losses may hinder expansion efforts and delay a return to profitability despite growing demand for minimally invasive therapies.Read more
EDAP TMS S.A., a medical technology company, engages in the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution segments. The HIFU segment develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. This segment also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL segment manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters. This segment also sells spare parts and disposables, such as electrodes. The Distribution segment markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.
